Boehringer Buys Nerio Therapeutics for $1.3B to Boost Immuno-Oncology Pipeline
The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% reduction...
Brainomix and Boehringer Launch Strategic Partnership in Fibrosing Lung Disease
In the year since the Humira biosimilar floodgates opened, AbbVie’s star immunology player has proven tough to drown out. In a new effort to crack the popular immunology drug’s 82% grasp on the market, Boehringer Ingelheim partnered up with GoodRx to offer its interchangeable version at a steep discount.
July 18 (Reuters) - A close copy version of Abbvie's (ABBV.N), opens new tab blockbuster arthritis drug Humira will be available at a 92% discount to its list price on the GoodRx website, the digital healthcare platform and German drugmaker Boehringer Ingelheim said on Thursday.
Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncologyFurther data read-outs expected in 2024 in oncology, mental health, and pulmonary fibrosisStrong first half net sales...
The Startup Incubation and Innovation Centre (SIIC), the technology business incubator of the Indian Institute of Technology Kanpur (IITK), has entered into an agreement with Boehringer Ingelheim India, a global pharmaceutical company, to foster healthcare innovation.
German Vice Chancellor and Federal Minister of Economics Robert Habeck inaugurates new biomass power plantIngelheim site can cover 95% of its energy needs from renewable sourcesNew power plant helps...
Boehringer and OSE to advance cancer immunotherapy to clinics
More than 1 billion people worldwide live with obesity, and numbers are continuing to rise. Estimations show that by 2035, 24% of the entire world population will be affected by this disease.1 Obesity is a major risk factor for other cardiovascular, renal, and metabolic (CRM) diseases as well as for several types of cancer, which collectively are a leading cause of death worldwide. With the progression of BI 3034701, Boehringer Ingelheim further expands its pipeline of patient-centric solutions beyond weight loss for people living with obesity to achieve CRM health gain.